Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SFT-1008
- Development stage
- Unknown
- Lead developer
- invoX Pharma
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
SFT-1008 (also referred to as IXT-001) is a drug candidate being developed by invoX Pharma (through its acquisition of Softhale NV) for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is a dry powder formulation of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA) combination, specifically glycopyrronium and indacaterol. The drug is delivered using the proprietary Softhaler® technology, a high-performance, propellant-free, multi-dose dry powder inhaler designed to deliver medication effectively to the lungs with low inspiratory effort. The program aims to provide a more efficient delivery of established bronchodilator therapies to improve lung function and symptom management in patients with COPD.
02
Targets
ADRB2 (β2)CHRM3 (M3)
Beyond the preview
Go deeper on SFT-1008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SFT-1008.